Did WW beat or miss consensus estimates last quarter?

What were the key takeaways from WW’s earnings call?

What guidance did WW's management provide for the next earnings period?

What factors drove the changes in WW's revenue and profit?

What is the market's earnings forecast for WW next quarter?

What is WW's gross profit margin?

What were the key takeaways from WW's earnings call?

What is the revenue and EPS growth rate for WW year over year?

- **Clinical Growth**: 35% YoY revenue increase, 60% YoY subscriber growth, and 19%-26% weight loss success rates.
- **Digital Transformation**: 2026 app/website redesign to unify medical and behavioral programs with AI.
- **Partnerships**: Amazon Pharmacy, NovoCare, and LillyDirect for medication access and delivery.
- **Menopause Program**: Targets 1.3M U.S. women, with strong early engagement.
- **Challenges**: Behavioral subscribers down 20% YoY, but improving from Q2 lows.
- **Upcoming Catalysts**: Oral GLP-1 launch in early 2026 and peak season marketing push.

**【CEO Summary Section】**
- Emphasized integration of medical solutions (e.g., GLP-1 medications) with traditional behavioral programs, achieving 19%-23% weight loss for clinic members vs. 12% for competitors.
- Launched WeightWatchers Clinic (formerly Weekend Health) and Menopause program, targeting 1.3M U.S. women annually.
- Announced app and website redesign for 2026, aiming to unify clinical and behavioral experiences with AI-driven personalization.
- Highlighted strategic partnerships with Novo Nordisk, LillyDirect, and Amazon Pharmacy for medication access and delivery.

**【CFO Financial Commentary】**
- Q3 2025 Revenue: $172M (-11% YoY), with clinical revenue up 35% YoY and behavioral down 16% YoY.
- Clinical subscribers: 124K (+60% YoY), behavioral subscribers: 2.9M (-20% YoY).
- Adjusted EBITDA: $43M (24.9% margin), cash: $170M, and $100M annual run-rate savings.
- ARPU: $18.52 (+9% YoY), driven by clinical mix shift.
- Q4 2025 outlook: Higher marketing spend for peak season, potential EBITDA decline.

**【Q&A Key Highlights】**
- **App Launch**: First version expected early 2026, with modern UI and integrated clinical/behavioral tools.
- **Retention**: Clinic retention exceeded expectations, with 20% of compounded semaglutide users transitioning to branded/oral meds.
- **Menopause Program**: Targeting new and lapsed members, with Queen Latifah campaign boosting brand visibility.
- **GLP-1 Landscape**: Anticipated oral medication launch in early 2026 as key growth driver.
- **Challenges**: Behavioral business still facing headwinds, but improving from Q2 lows.

**【Strategic Priorities】**
- Unified digital experience with AI-driven personalization.
- Expanded medical business (e.g., GLP-1 Companion Program, cash-pay dietitians).
- Brand modernization and value-based pricing strategy.
- Operational efficiency improvements (e.g., AI voice support, clinical/behavioral integration).

WW International, Inc. (WW) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

WW

WW fundamentals

You can ask Aime